Clinical Proteomics Innovator Complete Omics Secures Tens of Millions in Series A Funding Led by Qiming Venture Partners

VCBeat has learned at the earliest opportunity that,Recently, Complete Omics (Kangpu Bio), an emerging player in clinical proteomics, announced the completion of its multi-million-dollar Series A financing round, which was exclusively invested by Qiming Venture Partners.The proceeds from this round of financing will continue to be used for the research and development, clinical studies, and market promotion of Complete Omics’ innovative products.

Complete OmicsFounded in 2019, we are a cutting-edge biotechnology company focused on the clinical application development of proteomics. Dedicated to addressing core challenges in clinical proteomics, we have developed over 20 patented technologies that enable stable, high-throughput, and precise detection of numerous disease-related proteins and targets in bodily fluids and clinical samples. This has facilitated our transition of proteomics from research settings to clinical applications.

Currently, molecular diagnostic technologies for chronic diseases (such as cancer) remain predominantly based on genomics and sequencing. Although various novel multi-omics diagnostic approaches are being explored in the current market, they generally suffer from insufficient depth and reproducibility in biomarker detection due to limitations in data acquisition methods. Consequently, these technologies still fall short of meeting the rigorous, high-standard, and precise requirements for clinical application.

In recent years, proteomics technologies have garnered increasing attention in both academic and healthcare sectors. A surge of emerging companies has been observed, with numerous NASDAQ-listed firms such as Olink and Somalogic appearing overseas, while several domestic proteomics enterprises based on diverse technologies have also emerged in China. Recently, Thermo Fisher Scientific, a leader in the life sciences industry, announced its impending acquisition of Olink for $3.1 billion, sparking extensive new discussions within the proteomics market. Currently, the primary application of proteomics remains focused on research services, with limited progress in addressing urgent clinical needs such as disease screening and companion diagnostics. Achieving stable, high-throughput, and precise quantitative protein detection in commonly used clinical samples has gradually become a core challenge that requires urgent resolution for the clinical application of proteomics.

Complete OmicsDeveloped Complete360^®The technology platform enables precise and highly reproducible quantification of thousands of protein biomarkers, covering proteins associated with the integumentary, skeletal, muscular, lymphatic, respiratory, digestive, nervous, endocrine, cardiovascular, and urogenital systems. Furthermore, in the fields of tumor immunotherapy and ultra-low-abundance target detection, the company’s Valid-NEO^®The technology platform enables absolute quantification of tumor neoantigens in trace amounts of tumor tissue at the single-cell level with ultra-high sensitivity. The company’s recent R&D achievements have been published in flagship issues of top-tier academic journals such as Science. Currently, Complete Omics’ clinical proteomics technology has achieved initial commercialization, and the company has entered into collaborative development agreements with multiple internationally renowned pharmaceutical companies and leading research institutions.

Complete OmicsCore members of the founding team have previously held positions at prestigious institutions such as Johns Hopkins University School of Medicine and AstraZeneca. They contributed to the completion of the first human proteome map in 2014 and the first human tumor genome sequencing in 2007. The team possesses nearly two decades of experience in clinical translational research across the fields of proteomics, genomics, and metabolomics. They have published more than 20 papers in leading academic journals, including *Science*, *Cell*, *Nature*, and *The New England Journal of Medicine* (*NEJM*), with their work cited over 50,000 times cumulatively.

Dr. Qing Wang, Founder and CEO of Complete OmicsHe stated, “First and foremost, I would like to express my gratitude for the recognition and strong support from Qiming Venture Partners. Amidst the current relatively tight financing environment both domestically and internationally, securing substantial investment from a top-tier venture capital firm like Qiming Venture Partners serves as a testament to the world-leading nature of our team’s technological platform and the company’s years of persistent dedication. Since its inception, Complete Omics has consistently upheld the scientific pursuit of pushing technological development to its limits. Meanwhile, our independently developed product lines have all achieved considerable and sustained profitability, earning recognition from industry experts. Looking ahead, Complete Omics will continue to drive innovation, striving to facilitate high-level clinical applications of proteomics and multi-omics technologies worldwide, with the aim of becoming a globally leading next-generation molecular diagnostics enterprise.”